Exceptional Blood Loss Anemia
For purpose of consideration of the use of hyperbaric oxygen (HBO2)
therapy, exceptional blood-loss anemia is by definition loss of
enough red blood cell mass to compromise sufficient oxygen delivery
to tissue in patients who cannot be transfused for medical or
religious reasons. Medical reasons may include the threat of
blood product incompatibility or concern for transmissible disease.
Religious beliefs may prohibit the receipt of transfused blood
products.
Red blood cells (RBCs)
contain the respiratory pigment hemoglobin (Hb). Hemoglobin
has the powerful ability to pick up oxygen as RBCs pass through the
blood vessels of the lungs. Hemoglobin then has the equally powerful
ability to off-load oxygen in the tissues of the body’s organ
systems. If plasma were the only vehicle to deliver dissolved
oxygen, each 100 ml of blood flowing to an organ system would carry
only 0.3 ml of gaseous oxygen. The consumption of oxygen by
human tissues far exceeds this. For instance, the kidney
extracts approximately 2 ml of oxygen for every 100 ml of blood
which circulates through it. From the same 100 ml of blood,
the brain extracts approximately 6.5 ml and the heart 10.5 ml of
oxygen.
In most instances,
humans average 15 grams of hemoglobin per 100 cc of blood.
Each gram of hemoglobin transports 1.34 ml of oxygen. This is
in addition to the oxygen carried by plasma. So, 100 ml of
blood, by containing 15 grams of hemoglobin, can carry approximately
20 ml of gaseous oxygen (1.34 ml X 15 g Hb = 20 ml of oxygen).
In the 1960s, the Dutch
thoracic surgeon Boerema demonstrated that one could exchange
transfuse piglets with a simulated plasma mixture of buffered normal
saline (Ringer’s Lactate solution), dextrose and dextran. In
this process, blood was removed from the blood vessels and the
substitute liquid (without hemoglobin) replaced. He then
pressurized the piglets in a hyperbaric chamber while the animals
breathed 100% oxygen. By the trick of pressurization, enough
oxygen could be dissolved in the simulated plasma mixture to supply
tissue oxygen requirements. This was enough to adequately
sustain the animal, as evidenced by the fact that the animals
survived and could be brought out of the chamber to be successfully
re-exchange transfused with their previously extracted blood.
As hyperbaric oxygen (or
for that matter normobaric oxygen) administered for long periods can
become toxic, intermittent administration of HBO2 is
essential. This point has been demonstrated clinically by the
American thoracic surgeon, George Hart. In 1974, he reported a
series of 26 severe blood loss patients who were treated with HBO2
as an alternative to otherwise disallowed red blood cell
transfusion. The survival rate was 70%.
Alternative approaches
include use of fluorocarbons or stroma-free hemoglobin. While
potentially promising, these treatment solutions still pose
uncertainties for their potential ability to unfavorably alter the
immune system. While erythropoietin may be used to stimulate
the bone marrow to produce RBCs, HBO2 therapy only
complements its use in exceptional blood-loss anemia. |